Xiaohong Huang

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>

Claire Wainwright, J.S. Elborn, Bonnie W. Ramsey et al. · New England Journal of Medicine · 2015 · 1.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial

Michael Boyle, Scott C. Bell, Michael W. Konstan et al. · The Lancet Respiratory Medicine · 2014 · 442 citations

Pharmacy, Molecular Genetics, Pharmacotherapy +11

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

Kristian Reich, Henrique D. Teixeira, Marjolein de Bruin‐Weller et al. · The Lancet · 2021 · 389 citations

Medicine, Dermatology, Pediatrics +16

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial

Félix Ratjen, Christopher Hug, Gautham Marigowda et al. · The Lancet Respiratory Medicine · 2017 · 295 citations

Medicine, Pediatrics, Pharmacotherapy +12

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study

Michael W. Konstan, Edward F. McKone, Richard B. Moss et al. · The Lancet Respiratory Medicine · 2016 · 286 citations

Life Sciences, Genetics, Pharmacotherapy +15